About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 276808, 9 pages
http://dx.doi.org/10.1155/2013/276808
Research Article

Frataxin mRNA Isoforms in FRDA Patients and Normal Subjects: Effect of Tocotrienol Supplementation

1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40126 Bologna, Italy
2Department of Pharmaceutical Sciences, University of Ferrara, 44100 Ferrara, Italy
3ANFFAS ONLUS Macerata, 62100 Macerata, Italy
4Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna, 40100 Bologna, Italy
5Biocomputing Group, CIRI-Health Science and Technology, Department of Biology, Bologna 40126, Italy

Received 15 April 2013; Revised 6 August 2013; Accepted 17 August 2013

Academic Editor: Chen-Hsiung Hung

Copyright © 2013 Provvidenza Maria Abruzzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. B. Delatycki, R. Williamson, and S. M. Forrest, “Friedreich ataxia: an overview,” Journal of Medical Genetics, vol. 37, no. 1, pp. 1–8, 2000. View at Scopus
  2. G. de Michele, F. Perrone, A. Filla et al., “Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients,” Neurology, vol. 47, no. 5, pp. 1260–1264, 1996. View at Scopus
  3. C. Gellera, B. Castellotti, C. Mariotti et al., “Frataxin gene point mutations in Italian friedreich ataxia patients,” Neurogenetics, vol. 8, no. 4, pp. 289–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Campuzano, L. Montermini, M. D. Moltò et al., “Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion,” Science, vol. 271, no. 5254, pp. 1423–1427, 1996. View at Scopus
  5. L. Pianese, M. Turano, M. S. Lo Casale et al., “Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of friedreich ataxia patients and carriers,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 7, pp. 1061–1063, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Pianese, A. Tammaro, M. Turano, I. de Biase, A. Monticelli, and S. Cocozza, “Identification of a novel transcript of X25, the human gene involved in friedreich ataxia,” Neuroscience Letters, vol. 320, no. 3, pp. 137–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Xia, Y. Cao, X. Dai et al., “Novel frataxin isoforms may contribute to the pathological mechanism of friedreich ataxia,” PLoS ONE, vol. 7, no. 10, Article ID e47847, 2012. View at Publisher · View at Google Scholar
  8. D. Sirano, R. Shigeta, Y. Chi, M. Ristow, and S. E. Shoelson, “Crystal structure of human frataxin,” The Journal of Biological Chemistry, vol. 275, no. 40, pp. 30753–30756, 2000. View at Scopus
  9. Y. He, S. L. Alam, S. V. Proteasa et al., “Yeast frataxin solution structure, iron binding, and ferrochelatase interaction,” Biochemistry, vol. 43, no. 51, pp. 16254–16262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Nair, S. Adinolfi, C. Pastore, G. Kelly, P. Temussi, and A. Pastore, “Solution structure of the bacterial frataxin ortholog, CyaY: mapping the iron binding sites,” Structure, vol. 12, no. 11, pp. 2037–2048, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. L. Bulteau, H. A. O'Neill, M. C. Kennedy, M. Ikeda-Saito, G. Isaya, and L. I. Szweda, “Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity,” Science, vol. 305, no. 5681, pp. 242–245, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Stehling, H. Elsässer, B. Brückel, U. Mühlenhoff, and R. Lill, “Iron-sulfur protein maturation in human cells: evidence for a function of frataxin,” Human Molecular Genetics, vol. 13, no. 23, pp. 3007–3015, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Adinolfi, C. Iannuzzi, F. Prischi et al., “Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS,” Nature Structural and Molecular Biology, vol. 16, no. 4, pp. 390–396, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Schmucker, A. Martelli, F. Colin et al., “Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/ NFS1/ISD11 iron-sulfur assembly complex,” PLoS ONE, vol. 6, no. 1, Article ID e16199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Gakh, S. Park, G. Liu et al., “Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity,” Human Molecular Genetics, vol. 15, no. 3, pp. 467–479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Santos, S. Lefevre, D. Sliwa, A. Seguin, J. M. Camadro, and E. Lesuisse, “Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 13, no. 5, pp. 651–690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Meier and G. Buyse, “Idebenone: an emerging therapy for friedreich ataxia,” Journal of Neurology, vol. 256, no. 1, pp. 25–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. J. Lagedrost, M. S. J. Sutton, M. S. Cohen et al., “Idebenone in friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA),” The American Heart Journal, vol. 161, no. 3, pp. 639–645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. D. R. Lynch, S. L. Perlman, and T. Meier, “A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia,” Archives of Neurology, vol. 67, no. 8, pp. 941–947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Jauslin, T. Meier, R. A. Smith, and M. P. Murphy, “Mitochondria-targeted antioxidants protect friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants,” The FASEB Journal, vol. 17, no. 13, pp. 1972–1974, 2003.
  21. W. Nachbauer, S. Hering, M. Seifert et al., “Effects of erythropoietin on frataxin levels and mitochondrial function in friedreich ataxia—a dose-response trial,” Cerebellum, vol. 10, no. 4, pp. 763–769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Boesch, B. Sturm, S. Hering, H. Goldenberg, W. Poewe, and B. Scheiber-Mojdehkar, “Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin,” Annals of Neurology, vol. 62, no. 5, pp. 521–524, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. B. B. Aggarwal, C. Sundaram, S. Prasad, and R. Kannappan, “Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases,” Biochemical Pharmacology, vol. 80, no. 11, pp. 1613–1631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Anderson, J. Qiu, and B. Y. Rubin, “EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia,” Biochemical and Biophysical Research Communications, vol. 310, no. 2, pp. 627–633, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Anderson, J. Qiu, and B. Y. Rubin, “Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia,” Biochemical and Biophysical Research Communications, vol. 306, no. 1, pp. 303–309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Nakamura, F. Furukawa, A. Nishikawa et al., “Oral toxicity of a tocotrienol preparation in rats,” Food and Chemical Toxicology, vol. 39, no. 8, pp. 799–805, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Tasaki, T. Umemura, T. Inoue et al., “Induction of characteristic hepatocyte proliferative lesion with dietary exposure of Wistar Hannover rats to tocotrienol for 1 year,” Toxicology, vol. 250, no. 2-3, pp. 143–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Chomczynski and N. Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Analytical Biochemistry, vol. 162, no. 1, pp. 156–159, 1987. View at Scopus
  29. P. M. Abruzzo, S. Di Tullio, C. Marchionni et al., “Oxidative stress in the denervated muscle,” Free Radical Research, vol. 44, no. 5, pp. 563–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. W. Pfaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, no. 9, article e45, 2001. View at Scopus
  32. N. Eswar, B. Webb, M. A. Marti-Renom et al., “Comparative protein structure modeling using Modeller,” Current Protocols in Bioinformatics, vol. 5, p. 5.6, 2006. View at Scopus
  33. R. A. Laskowski, M. W. MacArthur, D. S. Moss, and J. M. Thornton, “PROCHECK: a program to check the stereochemical quality of protein structures,” Journal of Applied Crystallography, vol. 26, part 2, pp. 283–291, 1993. View at Publisher · View at Google Scholar
  34. M. J. Sippl, “Recognition of errors in three-dimensional structures of proteins,” Proteins, vol. 17, no. 4, pp. 355–362, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Shi, A. Proteau, M. Villarroya et al., “Structural basis for Fe-S cluster assembly and tRNA thiolation mediated by IscS protein-protein interactions,” PLoS Biology, vol. 8, no. 4, Article ID e1000354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. G. M. Morris, R. Huey, W. Lindstrom et al., “Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Leidgens, S. de Smet, and F. Foury, “Frataxin interacts with Isu1 through a conserved tryptophan in its β-sheet,” Human Molecular Genetics, vol. 19, no. 2, Article ID ddp495, pp. 276–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. S. Armstrong, O. Khdour, and S. M. Hecht, “Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question,” The FASEB Journal, vol. 24, no. 7, pp. 2152–2163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Marmolino, “Friedreich's ataxia: past, present and future,” Brain Research Reviews, vol. 67, no. 1-2, pp. 311–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Marmolino, F. Acquaviva, M. Pinelli et al., “PPAR-γ agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the friedreich's ataxia therapy,” Cerebellum, vol. 8, no. 2, pp. 98–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Fang, Z. Kang, and C. Wong, “Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors,” Molecular Nutrition and Food Research, vol. 54, no. 3, pp. 345–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Li, A. Singh, D. R. Crooks et al., “Expression of human frataxin is regulated by transcription factors SRF and TFAP2,” PLoS ONE, vol. 5, no. 8, Article ID e12286, 2010. View at Publisher · View at Google Scholar · View at Scopus